Pharmacological management of cardiac cachexia: a review of potential therapy options

[1]  S. Anker,et al.  Muscle wasting and cachexia in heart failure: mechanisms and therapies , 2017, Nature Reviews Cardiology.

[2]  M. Tschöp,et al.  Therapeutic Potential of Targeting the Ghrelin Pathway , 2017, International Journal of Molecular Sciences.

[3]  Minhua Cheng,et al.  Dexmedetomidine ameliorates muscle wasting and attenuates the alteration of hypothalamic neuropeptides and inflammation in endotoxemic rats , 2017, PloS one.

[4]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[5]  P. Seferovic,et al.  Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure. , 2016, International journal of cardiology.

[6]  F. Romeiro,et al.  Cardiac Cachexia: Perspectives for Prevention and Treatment , 2016, Arquivos brasileiros de cardiologia.

[7]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[8]  J. Springer,et al.  Cardiac cachexia: hic et nunc , 2016, Journal of cachexia, sarcopenia and muscle.

[9]  S. Anker,et al.  Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. , 2016, European heart journal.

[10]  V. Sundaram,et al.  Gastrointestinal and Liver Issues in Heart Failure , 2016, Circulation.

[11]  N. Pendleton,et al.  Progesterone therapy for the treatment of non-cancer cachexia: a systematic review , 2016, BMJ Supportive & Palliative Care.

[12]  M. Scherrer-Crosbie.  Losartan: A new treatment for cardiac cachexia? , 2015, Journal of molecular and cellular cardiology.

[13]  S. von Haehling,et al.  The wasting continuum in heart failure: from sarcopenia to cachexia , 2015, Proceedings of the Nutrition Society.

[14]  M. Muscaritoli,et al.  Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting , 2015, Journal of cachexia, sarcopenia and muscle.

[15]  S. Anker,et al.  Treatment of cachexia: An overview of recent developments. , 2015, International journal of cardiology.

[16]  S. Anker,et al.  Treatment of cachexia: an overview of recent developments. , 2014, Journal of the American Medical Directors Association.

[17]  S. Anker,et al.  Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. , 2014, Journal of the American College of Cardiology.

[18]  S. Anker,et al.  Pharmacokinetics of Drugs in Cachectic Patients: A Systematic Review , 2013, PloS one.

[19]  G. Azhar,et al.  New Approaches to Treating Cardiac Cachexia in the Older Patient , 2013, Current Cardiovascular Risk Reports.

[20]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[21]  W. Mitch,et al.  Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. , 2013, The international journal of biochemistry & cell biology.

[22]  V. Florea,et al.  Mechanisms for Cachexia in Heart Failure , 2013, Current Heart Failure Reports.

[23]  S. Giovannini,et al.  Late-life enalapril administration induces nitric oxide-dependent and independent metabolic adaptations in the rat skeletal muscle , 2013, AGE.

[24]  S. Paiva,et al.  Heart failure-induced cachexia. , 2013, Arquivos brasileiros de cardiologia.

[25]  F. Iellamo,et al.  Testosterone and heart failure , 2012, Endocrine.

[26]  Venkatesan D. Vidi,et al.  Testosterone Supplementation in Heart Failure: A Meta-Analysis , 2012, Circulation. Heart failure.

[27]  K. Okoshi,et al.  Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure , 2010, International journal of experimental pathology.

[28]  S. Anker,et al.  Cardiac cachexia: a systematic overview. , 2009, Pharmacology & therapeutics.

[29]  J. Fildes,et al.  Immunological mechanisms of pentoxifylline in chronic heart failure , 2009, European journal of heart failure.

[30]  F. Booth,et al.  Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. , 2008, Journal of applied physiology.

[31]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[32]  G. Filippatos,et al.  Prognosis and therapy approaches of cardiac cachexia , 2006, Current opinion in cardiology.

[33]  G. Azhar,et al.  Nutrition and cardiac cachexia , 2006, Current opinion in clinical nutrition and metabolic care.

[34]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[35]  Stephan von Haehling,et al.  Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.

[36]  K. Hryniewicz,et al.  Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. , 2003, Journal of cardiac failure.

[37]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[38]  K. Kangawa,et al.  Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. , 2003, Current opinion in pharmacology.

[39]  Abdissa Negassa,et al.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.

[40]  P. Poole‐Wilson,et al.  The cardiac component of cardiac cachexia. , 2002, American heart journal.

[41]  W. Shimizu,et al.  Chronic Administration of Ghrelin Improves Left Ventricular Dysfunction and Attenuates Development of Cardiac Cachexia in Rats With Heart Failure , 2001, Circulation.

[42]  Yi-Ping Li,et al.  Tumor necrosis factor-α and muscle wasting: a cellular perspective , 2001, Respiratory research.

[43]  S. Anker,et al.  Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. , 1999, Chest.

[44]  K. Sliwa,et al.  Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy , 1998, The Lancet.

[45]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[46]  P. Ponikowski,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016 .

[47]  S. Anker,et al.  The gut and intestinal bacteria in chronic heart failure. , 2009, Current drug metabolism.

[48]  E. V. van Beek,et al.  Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. , 2006, European heart journal.